Table 4 Yearly costs of pharmacological therapies* used in the PCP scenario, rounded to the nearest euro, by gender (2001 prices).
From: Cost-effectiveness analysis of guidelines for antihypertensive care in Finland
Pharmacological subgroup | ATC code | male | female |
|---|---|---|---|
hydrochlorothiazide or trichlormethiazide and potassium-sparing agents | C03EA | 40 | 42 |
beta-blocking agents | C07A | 145 | 136 |
combination of metoprolol or bisoprolol and thiazides | C07B | 141 | 141 |
atenolol or metoprolol and other antihypertensives | C07F | 285 | 275 |
calcium channel blockers | C08 | 245 | 228 |
ACE inhibitors | C09A | 203 | 192 |
combination of ACE inhibitors and diuretics | C09BA | 233 | 228 |
combination of ACE inhibitors and calcium channel blockers | C09BB | 349 | 348 |
angiotensin II subtype 1 receptor antagonists | C09C | 251 | 250 |
combination of angiotensin II subtype 1 receptor antagonists and diuretics | C09D | 271 | 274 |